UDG Healthcare plc
Preliminary Announcement of Results
Year ended 30 September 2017
Strong full year performance, driven by organic growth and further acquisitions
28 November 2017: UDG Healthcare plc (“UDG Healthcare” or “Group”), a leading international healthcare services provider, announces its preliminary results for the year ended 30 September 2017, which reflects another year of strong growth and strategic progress for the Group.
|Profit before tax||92.8||26.1||118.9||17||23|
|Diluted earnings per share (EPS) (cent)||28.83||8.29||37.12||17||23|
|Diluted earnings per share (cent)||-||-||-||(100)||(100)|
|Total diluted earnings per share (cent)||28.83||8.29||37.12||(5)||(1)|
|Dividend per share (cent)||13.30||-||13.30||7||7|
|Net (debt)/cash ($’m)||(53.3)||143.2|
|Net (debt)/cash/annualised EBITDA (times)||(0.32)||1.05|
1. Adjusted operating profit, profit before tax and diluted EPS are stated before the amortisation of acquired intangible assets ($22.1m, pre-tax) and transaction costs ($4.0m, pre-tax).
2. Net revenue represents gross revenue adjusted for revenue associated with pass-through costs, for which the Group does not earn a margin.
3. The Group has classified its joint venture arrangement with Magir Limited as a discontinued operation and an asset held for sale. The discontinued operations in 2016 also included United Drug Supply Chain Services, United Drug Sangers, TCP Group and MASTA. The Group’s disposal of these operations was completed on 1 April 2016.